Tax withholding trims Emergent BioSolutions (EBS) SVP Jessica Perl’s stake

Rhea-AI Filing Summary

Emergent BioSolutions Inc. senior vice president and general counsel Jessica Perl reported an automatic share withholding related to equity compensation. On February 9, 2026, 918 shares of common stock were withheld at $11.03 per share to pay taxes on vesting restricted stock units. After this tax withholding, she directly beneficially owns 67,469 shares of Emergent BioSolutions common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Perl Jessica

Role SVP, General Counsel, Corp Sec

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	918	$11.03	$10K

Holdings After Transaction: Common Stock — 67,469 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Perl Jessica

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel, Corp Sec

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		F		918(1)	D	$11.03	67,469	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did EBS executive Jessica Perl report on this Form 4?

Jessica Perl reported an automatic tax-related transaction involving 918 shares of Emergent BioSolutions common stock. The shares were withheld on February 9, 2026, to cover taxes due upon vesting and settlement of restricted stock units granted as equity compensation.

How many Emergent BioSolutions (EBS) shares were withheld and at what price?

A total of 918 shares of Emergent BioSolutions common stock were withheld from Jessica Perl. The shares were valued at $11.03 per share, and the withholding was used to satisfy tax obligations triggered by restricted stock units vesting and settling.

How many EBS shares does Jessica Perl own after this Form 4 transaction?

Following the reported tax withholding, Jessica Perl beneficially owns 67,469 shares of Emergent BioSolutions common stock. These shares are reported as held directly, reflecting her remaining equity position after 918 shares were withheld to cover associated tax liabilities.

Was the EBS Form 4 transaction an open-market sale by Jessica Perl?

No, the transaction was not an open-market sale. The Form 4 footnote explains the 918 shares of common stock were withheld by Emergent BioSolutions solely to pay taxes related to the vesting and settlement of restricted stock units granted to Jessica Perl.

What is Jessica Perl’s role at Emergent BioSolutions (EBS)?

Jessica Perl serves as senior vice president, general counsel, and corporate secretary at Emergent BioSolutions. Her position is disclosed on the Form 4, where she reports equity-related transactions involving the company’s common stock, including the tax withholding of 918 shares from restricted stock unit vesting.